A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial

Affiliations

• ¹ Department of Hematology and Cancer Prevention in Chorzow, Faculty of Health Sciences Bytom, Silesian Medical University in Katowice, Katowice, Poland.
• ² Department of Hematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland.
• ³ Department of Medical Oncology, Kidwai Memorial Institute of Oncology, HCG Hospitals Bangalore, Bengaluru, India.
• ⁴ Department of Medical Oncology, Wrocław Medical University, Wrocław, Poland.
• ⁵ Russian Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation.
• ⁶ Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain.
• ⁷ Oncohematology Department, National Cancer Institute, Kiev, Ukraine.
• ⁸ Department of Hematology, Medical University of Bialystok, Poland.
• ⁹ Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine.
• ¹⁰ Department of Hematology and Pomeranian Academy in Slupsk, Department of Health Sciences, The Janusz Korczak State Hospital in Slupsk, Medical University of Bialystok, Bialystok, Poland.
• ¹¹ Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland.
• ¹² Novartis Pharma AG, Basel, Switzerland.
• ¹³ Novartis Pharma S.A.S., Paris, France.
• ¹⁴ Novartis Oncology, East Hanover, NJ, USA.